FDA’s Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone NDA

Cell Therapeutics announced that on Feb. 9, the FDA’s Oncologic Drugs Advisory Committee will review Cell Therapeutics’ resubmitted NDA for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in patients who failed two or more lines of prior therapy.
The Sacramento Bee